Objective To explore the antitumor efficacy of tumor-treating fields(TTFields)and identify potential molecular markers for predicting patient response to TTFields therapy.Methods The clinical and genetic data of 100 newly diagnosed glioblastoma(ndGBM)patients who underwent TTFields therapy at Huashan Hospital from August 2018 to June 2023 were analyzed retrospectively.An additional control group of 195 ndGBM patients who did not undergo TTFields therapy was selected.Kaplan-Meier analysis was utilized to assess survival differences between the TTFields therapy group and the control group,with intergroup comparisons performed using the log-rank test.Multivariate Cox regression analysis was employed to investigate factors influencing the efficacy of TTFields therapy.Results In the TTFields therapy group,the median overall survival(OS)was 23.0 months(95％CI=17-NA),whereas the control group exhibited a median OS of 15.1 months(95％CI=13-18).Median progression-free survival(PFS)in the TTFields therapy group was 17 months(95％CI=12-NA),compared to 12 months(95％CI=9～12)in the control group.Multivariate Cox regression analysis results revealed statistically significant effects of PTEN mutation(HR=0.15,95％CI:0.034-0.63)and EGFR amplification(HR=5.67,95％CI=1.455-22.05)on PFS in the TTFields therapy group(both P＜0.05).Additionally,TERT mutation significantly influenced OS in the TTFields therapy group(HR=3.96,95％CI=1.308-12.0,P＜0.05).Conclusions TTFields therapy significantly prolongs patient survival.PTEN mutation and EGFR amplification emerge as independent potential molecular markers for predicting PFS in response to TTFields therapy,while TERT mutation serves as a potential marker for predicting OS in TTFields-treated patients.
维普
万方数据
